Healthcare / BiotechnologyNasdaqGS
$2.46
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-32.3M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$75M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-32.4%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-45.5M · FCF $-40.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Net Income | $-45.5M | $-45.5M | $-38.5M | $-24.6M | $-32.9M | $-17.4M | $-11.2M | $668.6M | $-21.1M | $-33.1M | $-52.8M | $-37.5M | $-21.7M | $-9.9M |
| EPS | -1.49 | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | 14.44 | -0.59 | -0.95 | — | — | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-40.2M | $-40.2M | $-32.3M | $-19.1M | $-15.4M | $65.9M | $-68.9M | $-18.5M | $-16.7M | $-35.1M | $-50.8M | $-35.6M | $-13.1M | $-9.0M |
| Returns | ||||||||||||||
| ROE | -32.4% | -32.4% | -21.1% | -11.2% | -13.7% | -6.5% | -3.2% | 88.5% | -51.1% | -55.1% | -89.3% | -36.4% | -36.8% | -97.1% |
| Growth & Yield | ||||||||||||||
| EPS Growth | -18.3% | -18.3% | -55.6% | 25.0% | -86.2% | -61.1% | -102.5% | 2547.5% | 37.9% | — | — | — | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.